D.A.L. Morgan

6.3k total citations · 1 hit paper
153 papers, 4.0k citations indexed

About

D.A.L. Morgan is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, D.A.L. Morgan has authored 153 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 62 papers in Cancer Research and 26 papers in Surgery. Recurrent topics in D.A.L. Morgan's work include Breast Cancer Treatment Studies (61 papers), Breast Lesions and Carcinomas (20 papers) and Estrogen and related hormone effects (14 papers). D.A.L. Morgan is often cited by papers focused on Breast Cancer Treatment Studies (61 papers), Breast Lesions and Carcinomas (20 papers) and Estrogen and related hormone effects (14 papers). D.A.L. Morgan collaborates with scholars based in United Kingdom, United States and Switzerland. D.A.L. Morgan's co-authors include Ian O. Ellis, R.W. Blamey, Roger Dale, Kwok‐Leung Cheung, Patrick J. Bradley, Stewart G. Martin, C. Deehan, Bleddyn Jones, Emad A. Rakha and C.W. Elston and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

D.A.L. Morgan

145 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Total meniscectomy in adolescence. A thirty-year follow-up.

2000 792 citations D.A.L. Morgan et al. profile →

Peers

Countries citing papers authored by D.A.L. Morgan

Since Specialization

Citations

This map shows the geographic impact of D.A.L. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.A.L. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.A.L. Morgan more than expected).

Fields of papers citing papers by D.A.L. Morgan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.A.L. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.A.L. Morgan. The network helps show where D.A.L. Morgan may publish in the future.

Co-authorship network of co-authors of D.A.L. Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of D.A.L. Morgan. A scholar is included among the top collaborators of D.A.L. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.A.L. Morgan. D.A.L. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	4th Symposium on Primary Breast Cancer in Older Women 2017 ·Future Oncology ·Karen Collins, Maria Burton, Kate Lifford, D.A.L. Morgan, (unknown), Lynda Wyld	0
2	Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ 2016 ·The Breast ·John Mathew, (unknown), D.A.L. Morgan, A.H.S. Lee, Ian O. Ellis, J.F.R. Robertson, (unknown)	5
3	Can Folding a Product Foster Emotional Attachment 2014 ·D.A.L. Morgan	1
4	The potential value of comprehensive geriatric assessment in evaluating older women with primary operable breast cancer undergoing surgery or non-operative treatment — A pilot study 2014 ·Journal of Geriatric Oncology ·Ruth Parks, Louise Hall, (unknown), (unknown), (unknown), L. Winterbottom, D.A.L. Morgan, Davina Porock, Karen Cox, Kwok‐Leung Cheung	25
5	The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage 2012 ·Journal of Clinical Pathology ·Emad A. Rakha, D.A.L. Morgan, Douglas Macmillan	7
6	Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic 2011 ·Annals of Oncology ·Binafsha Manzoor Syed, Simon J. Johnston, (unknown), Andrew R. Green, L. Winterbottom, (unknown), Natalie E. Simpson, D.A.L. Morgan, Ian O. Ellis, Kwok‐Leung Cheung	24
7	Redox Protein Expression Predicts Radiotherapeutic Response in Early-Stage Invasive Breast Cancer Patients 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Caroline M. Woolston, Ahmad Al‐Attar, Sarah J. Storr, Ian O. Ellis, D.A.L. Morgan, Stewart G. Martin	24
8	Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy 2010 ·The Breast ·D.A.L. Morgan, (unknown), Kwok‐Leung Cheung	27
9	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy 2009 ·Critical Reviews in Oncology/Hematology ·Gbolahan W. Okunade, Andrew R. Green, Michael Ying, Amit Agrawal, Emma C. Paish, (unknown), L. Winterbottom, Karen Hassell, D.A.L. Morgan, Ian O. Ellis, Kwok‐Leung Cheung	9
10	Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’ 2008 ·European Journal of Cancer ·Sandra Collette, Laurence Collette, Tom Budiharto, Jean-Claude Horiot, Philip Poortmans, H. Struikmans, Walter Van den Bogaert, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, Rolf‐Peter Mueller, John M. Kurtz, D.A.L. Morgan, Jean‐Bernard Dubois, E. Salamon, R.O. Mirimanoff, M. Bolla, (unknown), Carla C. Wárlám-Rodenhuis, Harry Bartelink	157
11	The use of a commercial remote desktop program in the delineation of target volumes in radiotherapy 2008 ·British Journal of Radiology ·K A Langmack, Thomas Allmendinger, D.A.L. Morgan	8
12	The Role of Biologically Effective Dose (BED) in Clinical Oncology 2001 ·Clinical Oncology ·Bleddyn Jones, Roger Dale, C. Deehan, (unknown), D.A.L. Morgan	208
13	Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial 2000 ·The Lancet ·(unknown), (unknown), D.A.L. Morgan, (unknown)	84
14	The cosmetic outcome in early breast cancer treated with breast conservation 1999 ·European Journal of Surgical Oncology ·SK Al‐Ghazal, RW Blamey, John F. Stewart, D.A.L. Morgan	115
15	Expression of Interferon-β is Associated with Growth Arrest of Murine and Human Epidermal Cells 1999 ·Journal of Investigative Dermatology ·Diane R. Bielenberg, Marya F. McCarty, Corazon D. Bucana, Stuart H. Yuspa, D.A.L. Morgan, Jeffrey M. Arbeit, Lee M. Ellis, Karen R. Cleary, Isaiah J. Fidler	41
16	Setting Up Wound Dressing Guidelines: Avoiding The Pitfalls. 1998 ·Journal of Tissue Viability ·D.A.L. Morgan	4
17	A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma 1997 ·Clinical Oncology ·(unknown), D.A.L. Morgan	12
18	ABC of Breast Diseases: Management of regional nodes in breast cancer 1994 ·BMJ ·Nigel Bundred, D.A.L. Morgan, J. Michael Dixon	22
19	Immunoscintigraphy of small-cell lung cancer: a study using technetium and indium labelled anti-carcinoembryonic antigen monoclonal antibody preparations 1993 ·British Journal of Cancer ·(unknown), Alan C. Perkins, (unknown), (unknown), D.A.L. Morgan	3
20	Endothelial Prostaglandin Secretion: Effects of Typhus Rickettsiae 1990 ·The Journal of Infectious Diseases ·T S Walker, (unknown), (unknown), D.A.L. Morgan	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact